Anti-hyperlipidaemic assay and LC-MS/MS determination of piperinic ester in rat

doi:10.5246/jcps.2018.12.085

Abstract

Abstract:

In the present study, we aimed to establish high-fat diet model for evaluating anti-hyperlipidaemic activity of GBA and to establish the HPLC-MS method for measuring the pharmacokinetics of GBA in rat blood plasma and liver after oral administration. Rats were orally administrated with GBA at the dose of 50mg/kg body weight. GBA concentrations in blood plasma and liver were detected by HPLC from 0.5–10 h post administrations. The pharmacokinetic parameters were analyzed by the DAS1.0Software. The concentration-time curves of the plasma GBA and liver GBA wereconformed to two-compartment model. GBA was rapidly absorbed in the gastrointestinal tract and could be detected in plasma and liver 0.5 h after oral administration.

Key words: Long pepper, Piperinic ester GBA, Antihyperlipidaemic activity, LC-MS/MS analysis

CLC Number:

R917

Supporting:

Bo Surina, Dan Mu, Ochir Sarangua, Chunjie Ma. Anti-hyperlipidaemic assay and LC-MS/MS determination of piperinic ester in rat[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(12): 840-846.

References

[1] Nelson, R.H. Hyperlipidemia as risk factor for cardiovascular disease. Prim. Care. 2013, 40, 195-211.

[2] Sattar, N.; Preiss, D.; Murray, H.M.; Welsh, P.; Buckley, B.M.; CraenAnton, J.M.D.; Seshasai, S.R.K.; McMurray, J.J.; Freeman, D.J.; Jukema, J.W.; Macfarlane, P.W.; Packard, C.J.; Stott, D.J.; Westendorp, R.G.; Shepherd, J.; Davis, B.R.; Pressel, S.L. Statin and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010, 375, 735-742.

[3] Preiss, D.; Seshasai, S.R.; Welsh, P.; Murphy, S.A.; Ho, J.E.; Waters, D.D.; DeMicco, D.A.; Barter, P.; Cannon, C.P.; Sabatine, M.S.; Braunwald, E.; Kastelein, J.J.; de Lemos, J.A.; Blazing, M.A.; Pedersen, T.R.; Tikkanen, M.J.; Sattar, N.; Ray, K.K. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011, 305, 2556-2564.

[4] Preiss, D.; Tikkanen, M.J.; Welsh, P., Ford, I.; Lovato, L.C.; Elam, M.B.; LaRosa, J.C.; DeMicco, D.A.; Colhoun, H.M.; Goldenberg, I.; Murphy, M.J.; MacDonald, T.M.; Pedersen, T.R.; Keech, A.C.; Ridker, P.M.; Kjekshus, J.; Sattar, N.; McMurray, J.J. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA. 2012, 308, 804-811.

[5] Hai, Y.; Nashengsang; Shuang, F. Teratogenicity of Pepper Alkali. Modern. Tradit. Chin. Med. Materia Materia-World Sci. Tech. 2008, 10, 133-136.

[6] Jin, Z.; Borjihan, G.; Zhao, R.G.; Sun, Z.; Hammond, G.B.; Uryu, T. Antihyperlipidemic compounds from the fruit of piper longum L. Phytother. Res. 2009, 23, 1194-1196.

[7] Erdenebaatar, S.; Borjihan, G.; Sun, Z. The preparation and antihyperlipidemic assay of piperlonguminine in vivo. Phytochem. Lett. 2013, 6, 101-105.

[8] Wu, Y.; Borijihan, G. Synthesis of piperinic esters and their antlipidic effect. J. Med Pharm. Chin. Minorities. 2004, 2, 23-24.

[9] Su, R.N.; Borjihan, G.; Ma, C.J.; Mu, D.; Na, R.S.; Te, G.X. Study on antihyperlipidemia effect and acute toxicity test of piperinic ester. Lishizhen Med. Mater Med. Res. 2016, 27, 1318-1320.

[10] FDA. Guidance for industry: Bioanalytical method validation. U.S. Department of Health and Human Services. 2001, 5.

[11] Shah, V.P.; Midha, K.K.; Findlay, J.W.A; Hill , H.M.; Hulse, J.D.; McGilveray, I.J.; McKay, G.; Miller, K.J.; Patnaik, R.N.; Powell, M.L.; Tonelli, A.; Viswanathan, C.T.; Yacobi, A. Bioanalytical method validation—A revisit with decade of progress. Pharm. Res. 2000, 17, 1551-1557.

[12] Miller, J.N.; Miller, J.C. Statistics and chemometrcs for analytical chemistry. Fiftieth ed. 2005, Tottenham. England.

[13] Reza, A.; Noushin, R.; Syed, H.H.M.; Effat, S. Development and validation of a sensitive HPLC method for the determination of lisinopril in human plasma after derivatization with 4-fluoro-7-nitro-2,1,3-benzoxadiazole. J. Chin. Pharm. Sci. 2018, 27, 623-629.

[14] Zhang, X.G.; Liu J.W.; Kou, F.; Wang, Q.L.; Liu, Z.Y.; Li, J.Y. Bioavailability and pharmacokinetics of alantolactone from Inula helenium in rats following intravenous and oral administrations, J. Chin. Pharm. Sci. 2017, 26, 284-290.

[15] Chen, X.; Ma, Y.M.; Zhong, J. Research progress in double peak phenomenon of concentration-time curve. Chin. J. New Drugs Clin. Rem. 2012, 31, 432-437.

[16] Huang, Y.; Bai, Y.; Zhao, L.B.; Hu, T.; Hu, B.R.; Wang J.L. Pharmacokinetics and metabolism of neferine in rats after a single oral administration. Biopharm. Drug Dispos. 2007, 28, 361-372.